194.11MMarket Cap-6.18P/E (TTM)
18.172High17.330Low58.23KVolume18.100Open18.000Pre Close1.04MTurnover0.78%Turnover RatioLossP/E (Static)10.79MShares24.00052wk High5.67P/B134.33MFloat Cap11.04052wk Low--Dividend TTM7.47MShs Float135.170Historical High--Div YieldTTM4.68%Amplitude7.100Historical Low17.842Avg Price1Lot Size
MediWound Stock Forum
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
Tuesday, 17th December at 8:00 am
YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. T...
·3 mins ago
Mediwound Announces U.S. Food and Drug Administration Approval of Nexobrid® for the Treatment of Pediatric Patients With Severe Thermal Burns
No comment yet